Simulations Plus Wins Phase II Small Business Innovation Research Grant

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of software for pharmaceutical discovery and development, today announced that it was notified by the National Cancer Institute (NCI) that the company has been awarded a $525,000 Phase II Small Business Innovation Research (SBIR) grant. The NCI is an agency of the National Institutes of Health of the U.S. Department of Health and Human Services. The grant, which is disbursed over two years, is for Simulations Plus to further enrich the predictive capabilities of its best-in-class ADMET Predictorâ„¢ software product. ADMET Predictor is a software research tool used worldwide by pharmaceutical scientists to estimate absorption, distribution, metabolism, excretion, and toxicity properties of pharmaceutical compounds and to build advanced mathematical models.

Back to news